{
  "id": 4642421,
  "title": "Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide",
  "url": "https://urgent.news/2026/08/31/arch-biopartners-receives-central-irb-approval-to-support-u-s-sites",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-31T12:23:48.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/arch-biopartners-receives-central-irb-approval-to-support-u-s-sites-in-phase-ii-cardiac-surgery-associated-acute-kidney-injury-trial-of-lsalt-peptide"
  },
  "original_language": "en",
  "account": null,
  "summary": "TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has received central Institutional Review Board (“IRB”) approval of the protocol and related study documents for the Company’s ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (“CS-AKI”). Arch recently announced […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}